Prof William V Tamborlane MD Ensio Norjavaara MD Summary Background Since there are few treatment options for young people with type diabetes we aimed to assess the efficacy and safety of dapagliflozin as add on therapy in children adolescents and young adults with type diabetes receiving metformin insulin or both Methods This multicentre placebo controlled double blind randomised phase study was undertaken at centres in five countries Hungary Israel Mexico Russia and the USA Participants aged years with type diabetes and HbA c concentration of mmol mol were randomly assigned to oral dapagliflozin mg or placebo during a week double blind period which was then followed by a week open label safety extension in which all participants received dapagliflozin Participants and study personnel were masked and participants were randomly assigned treatment placebo or study drug using an interactive web and voice response system The primary outcome was between group differences in change in HbA c concentration from baseline to weeks intention to treat analysis A prespecified sensitivity analysis of the primary outcome was also assessed in the per protocol population which included only protocol compliant participants This trial is registered with ClinicalTrials gov NCT Interpretation The primary outcome of change in HbA c concentration was not significant in the intention to treat analysis of children adolescents and young adults with type diabetes receiving dapagliflozin in addition to standard of care treatment A prespecified sensitivity analysis of protocol compliant participants showed a significant difference in HbA c concentration between groups No new safety signals were identified and there was a low risk of severe hypoglycaemia Sources 